Kyowa Kirin (4151.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4151.T · Stock Price

JPY 2,326+186 (+8.69%)

Market Cap: $7.8B

Historical price data

Market Cap: $7.8BPipeline: 200 drugs (67 Phase 3)Patents: 20Founded: 1949Employees: 5,669HQ: Tokyo, Japan

Sector Ranking#7 in Biologics / Biosimilars #1 in Rare & Orphan Diseases

Overview

Kyowa Kirin is a global specialty pharmaceutical leader with a mission to deliver 'life-changing value' by addressing high unmet medical needs through innovative antibody and gene therapies. The company has successfully transitioned into a global player, deriving 72% of its sales from international markets and maintaining a robust pipeline of 18 development programs. Its strategy is anchored in proprietary technology platforms like POTELLIGENT, strategic acquisitions such as Orchard Therapeutics, and a focused therapeutic approach in bone & mineral, hematologic, and rare diseases to drive sustainable growth towards its Vision 2030.

Bone & Mineral DiseasesHematologic MalignanciesRare Diseases

Technology Platform

Proprietary antibody engineering platforms (POTELLIGENT, COMPLEGENT) for enhanced efficacy and a fully integrated hematopoietic stem cell gene therapy (HSC-GT) platform for ex vivo autologous gene therapies.

Pipeline

200

200 drugs in pipeline67 in Phase 3

Drug	Indication	Stage
Istradefylline 20 mg or 40 mg	Idiopathic Parkinson's Disease	Phase 3
Placebo + KW-2246 (fentanyl citrate)	Pain, Cancer	Phase 3
KK8398	Achondroplasia	Phase 3
Istradefylline (KW-6002)	Parkinson's Disease	Phase 3
KHK4827 + Placebo	Moderate to Severe Plaque Psoriasis	Phase 3

FDA Approved Drugs

4

NOURIANZNDAAug 27, 2019

POTELIGEOBLAAug 8, 2018

CRYSVITABLAApr 17, 2018

Opportunities

Significant growth lies in the global expansion of its rare disease franchise, particularly the gene therapy platform acquired from Orchard Therapeutics, which targets ultra-rare disorders with curative one-time treatments.

Successful late-stage readouts for KHK4083 in atopic dermatitis and KW-6356 in Parkinson's disease could unlock large, new commercial markets and diversify the revenue base.

Risk Factors

Major risks include clinical failure of key late-stage pipeline assets, the immense commercialization and reimbursement challenges associated with multi-million dollar gene therapies, and revenue concentration risk as the company remains reliant on a small number of core marketed products facing future patent expirations.

Competitive Landscape

Kyowa Kirin competes in specialized, high-barrier niches: its bone drug faces limited direct competition, its lymphoma drug contends with other systemic therapies, and its gene therapies compete with other biotech firms in a capital-intensive, scientifically complex field. Its atopic dermatitis candidate, if approved, would enter a crowded market dominated by established biologics.